ARTICLE | Company News

Ocular Therapeutix, Regeneron deal

October 17, 2016 7:00 AM UTC

Ocular and Regeneron partnered to develop a sustained-release formulation of Regeneron’s ophthalmic drug Eylea aflibercept using Ocular’s hydrogel-based technology. Regeneron has an exclusive option to obtain worldwide rights to the formulation and other biologics targeting VEGF for ophthalmic indications. ...